DOCSLIB.ORG

Differential Effect of IFN -2B on the Cytochrome P450 Enzyme System

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Differential Effect of IFN -2B on the Cytochrome P450 Enzyme System 2480 Vol. 8, 2480–2487, August 2002 Clinical Cancer Research Advances in Brief Differential Effect of IFN␣-2b on the Cytochrome P450 Enzyme System: A Potential Basis of IFN Toxicity and Its Modulation by Other Drugs1 Mohammed Islam, Reginald F. Frye, Conclusion: These data suggest that strategies to mini- Thomas J. Richards, Ibraham Sbeitan, mize the impairment of CYP enzymes could alter the toxic- Sandra S. Donnelly, Paul Glue, ity profile of HDI and augment its therapeutic utility, and 2 that recognition of these potential interactions is important Sanjiv S. Agarwala, and John M. Kirkwood in the therapeutic application of IFNs. Melanoma Center, University of Pittsburgh Cancer Institute [M. I., T. J. R., I. S., S. S. D., S. S. A., J. M. K.], Department of Medicine, School of Medicine [J. M. K.], and Department of Pharmaceutical Introduction Sciences, School of Pharmacy and Center for Clinical Pharmacology IFNs are cellular proteins of 143–187 amino acids pro- [R. F. F.], University of Pittsburgh, Pittsburgh, Pennsylvania 15213, duced by stimulated immune and nonimmune cells that exhibit and Schering Plough Research Institute, Kennilworth, New Jersey antiviral, differentiating, antiproliferative, and immunomodula- 07033 [P. G.] tory functions. IFN␣-2b exhibits variable therapeutic responses when used in combination with various chemotherapies and Abstract cytokines in metastatic melanoma (1–3). However, no therapy Purpose: High-dose IFN␣-2b therapy (HDI) is the has yet demonstrated unequivocal effects on survival in patients standard of adjuvant therapy for patients with high-risk with metastatic disease. In the adjuvant setting, survival and melanoma, but toxicities of this regimen have limited its relapse-free interval were significantly prolonged in the pivotal application. IFNs affect cytochrome P450 (CYP) enzymes, E1684 trial of the Eastern Cooperative Oncology Group, and in which metabolize many endogenous (e.g., steroids, fatty ac- the most recent intergroup trial E1694 (4, 5). Despite the sig- 3 ids) and exogenous (e.g., drugs) substrates. No systematic nificant therapeutic gain associated with adjuvant HDI therapy, studies have been performed to evaluate the effect of HDI on toxicity and adverse effects have impeded adoption of this CYP enzymes. A significant inhibitory effect of HDI on CYP therapy by physicians and patients. Approximately 78% of enzymes would increase the potential for adverse drug re- patients receiving IFN therapy in E1684 experienced grade 3 actions and altered homeostasis through effects on hormone toxicity, and 24% discontinued therapy because of this toxicity metabolism. (6, 7). The management or prevention of toxicities associated Methods: To evaluate the potential effect of HDI on with HDI therapy is one of the greatest challenges in broadening CYP enzymes, 17 patients with high-risk melanoma were and improving the efficacy of this regimen. treated with HDI, and CYP enzyme activity was measured The CYP enzymes are a superfamily of heme-containing by administration of selectively metabolized probe drugs enzymes distributed widely throughout the body that are in- -over time (days ؊6, ؉1, ؉26, and ؉52 of HDI). Probe drugs volved in the synthesis and metabolism of endogenous sub and/or metabolites were quantified and used to derive in- strates including steroid hormones, fatty acids, and lipids, as dexes of enzyme activity. well as the metabolism of exogenous substrates such as drugs Results: The results indicate that HDI differentially and environmental chemicals. IFNs have been shown to de- impairs CYP-mediated metabolism, having no effect on crease the expression and activity of CYP enzymes in animal some enzymes (CYP2E1) and substantial effects on others models (8–11). Human data are less extensive and primarily (CYP1A2; median 60% decrease). A significant association limited to patients with hepatitis being treated with compara- was found between the magnitude of CYP inhibition and the tively low-dose IFNs (12–15), but the available data indicate a occurrence of side effects including fever and neurological detrimental effect on drug metabolism. However, the selectivity toxicity, which may form a novel basis of the underlying and magnitude of the effect on individual drug metabolizing pathophysiology of some IFN␣-2b-induced toxicity. enzymes is largely unknown. In addition, there are no data on the effect of HDI used to treat patients with melanoma on drug-metabolizing enzymes. A deleterious effect on the CYP enzyme system would have important consequences because of Received 11/16/01; revised 3/23/02; accepted 4/2/02. the increased potential for drug-induced adverse effects related The costs of publication of this article were defrayed in part by the to concomitant drug treatment (i.e., drug-cytokine interactions) payment of page charges. This article must therefore be hereby marked and also the potential for altering homeostasis through effects on advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 1 Supported in part by NIH/NCRR/GCRC Grant #5M01 RR00056. 2 To whom requests for reprints should be addressed, at Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh 3 The abbreviations used are: HDI, high-dose IFN␣-2b; AUC, area Medical Center, 200 Lothrop Street, Montefiore Hospital N-755, Pitts- under the plasma concentration-time curve; Cmax, maximum observed burgh, PA 15216. Phone: (412) 648-6571; Fax: (412) 648-6599; E-mail: serum concentration; CYP, cytochrome P450; IL, interleukin; Tmax, [email protected]. time to achieve maximum serum concentration. Downloaded from clincancerres.aacrjournals.org on October 2, 2021. © 2002 American Association for Cancer Research. Clinical Cancer Research 2481 Table 1 Schema of study designed to evaluate the differential effect of HDI therapy on the CYP enzyme system Table 2 Five probe drugs regimen or “Pittsburgh mixture” and their doses, corresponding CYP, and activity measure Probe drug (dose) Enzyme Specimen Trait measure Reference Caffeine (100 mg) CYP1A2 Plasma, 8 hours Paraxanthine/caffeine 16 Mephenytoin (100 mg) CYP2C19 Urine, 0–8 hours 4ЈOH-mephenytoin recovery 47 Debrisoquine (10 mg) CYP2D6 Urine, 0–8 hours DBRRa 18 Chlorzoxazone (250 mg) CYP2E1 Plasma, 4 hours 6-OH-chlorzoxazone/chlorzoxazone 17 Dapsone (100 mg) CYP2C8/9b Urine, 0–8 hours DPRRc 22 NATd Plasma, 8 hours MAD/DDSe a Debrisoquine recovery ratio, calculated as the urinary recovery of 4-Hydroxydebrisoquine divided by the sum of 4-Hydroxydebrisoquine and debrisoquine. b May also involve CYP3A4/5 and CYP2E1. c Dapsone recovery ratio calculated as the urinary recovery of dapsone hydroxylamine divided by the sum of dapsone hydroxylamine and dapsone. d NAT, N-acetyltransferase. e MAD, monoacetyldapsone; DDS, dapsone. endogenous substrates such as hormones. Thus, this study was of s.c. IFN␣-2b) as shown in Table 1. CYP enzyme activities conducted to examine the effects of acute and chronic high-dose were estimated in vivo using the “Pittsburgh mixture” approach, IFN␣-2b monotherapy on several important drug-metabolizing which involves the simultaneous oral administration of five CYP enzymes in vivo using known enzyme-selective probe drugs for which the metabolism has been well characterized. drugs (16–18). Each patient received the mixture of five drugs during each visit as shown in Table 2. We have shown previously that there is no Patients and Methods interaction between the mixture drugs at the doses given (20). Study Design. Seventeen patients with high-risk, re- Blood samples (20 ml) were obtained at 0, 4, and 8 h, and urine sected melanoma who were scheduled to undertake adjuvant was collected from 0 to8htomeasure the concentration of therapy with high-dose IFN␣-2b participated in this study after probe drugs and/or their metabolites. Plasma harvested by cen- providing written informed consent. Eligibility criteria included trifugation, and urine aliquots were stored frozen at Ϫ20°C until biopsy-proven high-risk melanoma, normal renal (serum creat- analyzed. The probe drugs and their metabolites were analyzed inine Ͻ2.0 mg/dl) and liver function (total bilirubin Ͻ1.5 mg/ by high-performance liquid chromatography for the determina- dl), and no history of allergy to sulfa drugs. All of the subjects tion of caffeine and paraxanthine, (21), 4-hydroxymephenytoin, were instructed to abstain from alcohol, caffeine, barbecued (20), debrisoquine, and 4-hydroxydebrisoquine (18), chlorzoxa- meat, and grapefruit or grapefruit juice consumption for at least zone and 6-hydroxychlorzoxazone (17), dapsone and N- 2 days before each visit (19). Patients with other underlying hydroxydapsone in urine, and dapsone and monoacetyldap- medical diseases taking drugs known to affect the CYP enzyme sone in plasma (22). Probe drug analyses were conducted system that could not be safely interrupted were excluded from such that all of the samples for a given patient were analyzed the study. within the same run so as to minimize within-subject varia- All of the patients received i.v. IFN-␣2b (INTRON A; tion because of analytical procedures. The interday coeffi- Schering Plough, Kenilworth, NJ) at a dose of 20 million units cients of variation for each of these assays were Ͻ15%. In (MU)/m2/day for 5 days/week ϫ 4 weeks (induction phase) addition, all of the assay procedures were cross-validated to followed by s.c. IFN-␣2b at a dose of 10 MU/m2/day for 3 ensure that no analytical interference would occur with si- days/week ϫ 48 weeks (maintenance
Load more

Recommended publications
  • Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid
    Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 231 _____________________________ _____________________________ Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid Cloning, Expression and Catalytic Properties of CYP4F8 and CYP4F21 BY JOHAN BYLUND ACTA UNIVERSITATIS UPSALIENSIS UPPSALA 2000 Dissertation for the Degree of Doctor of Philosophy (Faculty of Pharmacy) in Pharmaceutical Pharmacology presented at Uppsala University in 2000 ABSTRACT Bylund, J. 2000. Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid: Cloning, Expression and Catalytic Properties of CYP4F8 and CYP4F21. Acta Universitatis Upsaliensis. Comprehensive Summaries of Uppsala Dissertations from Faculty of Pharmacy 231 50 pp. Uppsala. ISBN 91-554-4784-8. Cytochrome P450 (P450 or CYP) is an enzyme system involved in the oxygenation of a wide range of endogenous compounds as well as foreign chemicals and drugs. This thesis describes investigations of P450-catalyzed oxygenation of prostaglandins, linoleic and arachidonic acids. The formation of bisallylic hydroxy metabolites of linoleic and arachidonic acids was studied with human recombinant P450s and with human liver microsomes. Several P450 enzymes catalyzed the formation of bisallylic hydroxy metabolites. Inhibition studies and stereochemical analysis of metabolites suggest that the enzyme CYP1A2 may contribute to the biosynthesis of bisallylic hydroxy fatty acid metabolites in adult human liver microsomes. 19R-Hydroxy-PGE and 20-hydroxy-PGE are major components of human and ovine semen, respectively. They are formed in the seminal vesicles, but the mechanism of their biosynthesis is unknown. Reverse transcription-polymerase chain reaction using degenerate primers for mammalian CYP4 family genes, revealed expression of two novel P450 genes in human and ovine seminal vesicles.
    [Show full text]
  • Functional Characterization of Eight Human Cytochrome P450 1A2 Gene Variants by Recombinant Protein Expression
    The Pharmacogenomics Journal (2010) 10, 478–488 & 2010 Macmillan Publishers Limited. All rights reserved 1470-269X/10 www.nature.com/tpj ORIGINAL ARTICLE Functional characterization of eight human cytochrome P450 1A2 gene variants by recombinant protein expression B Brito Palma1,2, M Silva e Sousa1, Inter-individual variability in cytochrome P450 (CYP)-mediated xenobiotic 2 2 metabolism is extensive. CYP1A2 is involved in the metabolism of drugs CR Vosmeer , J Lastdrager , and in the bioactivation of carcinogens. The objective of this study was 1 2 JRueff,NPEVermeulen to functionally characterize eight polymorphic forms of human CYP1A2, and M Kranendonk1 namely T83M, S212C, S298R, G299S, I314V, I386F, C406Y and R456H. cDNAs of these variants were constructed and coexpressed in Escherichia coli 1Department of Genetics, Faculty of Medical with human NADPH cytochrome P450 oxidoreductase (CYPOR). All variants Sciences, Universidade Nova de Lisbon, Lisbon, showed similar levels of apoprotein and holoprotein expression, except for Portugal and 2Division of Molecular Toxicology, Department of Pharmacochemistry, LACDR, Vrije I386F and R456H, which showed only apoprotein, and both were functionally Universiteit Amsterdam, Amsterdam, The inactive. The activity of CYP1A2 variants was investigated using 8 substrates, Netherlands measuring 16 different activity parameters. The resulting heterogeneous activity data set was analyzed together with CYP1A2 wild-type (WT) form, applying Correspondence: Dr M Kranendonk, Department of Genetics, multivariate analysis. This analysis indicated that variant G299S is substantially Faculty of Medical Sciences, Universidade Nova altered in catalytic properties in comparison with WT, whereas variant T83M is de Lisbon, Rua da Junqueira 96, 1349-008 slightly but significantly different from the WT.
    [Show full text]
  • Simulation of Physicochemical and Pharmacokinetic Properties of Vitamin D3 and Its Natural Derivatives
    pharmaceuticals Article Simulation of Physicochemical and Pharmacokinetic Properties of Vitamin D3 and Its Natural Derivatives Subrata Deb * , Anthony Allen Reeves and Suki Lafortune Department of Pharmaceutical Sciences, College of Pharmacy, Larkin University, Miami, FL 33169, USA; [email protected] (A.A.R.); [email protected] (S.L.) * Correspondence: [email protected] or [email protected]; Tel.: +1-224-310-7870 or +1-305-760-7479 Received: 9 June 2020; Accepted: 20 July 2020; Published: 23 July 2020 Abstract: Vitamin D3 is an endogenous fat-soluble secosteroid, either biosynthesized in human skin or absorbed from diet and health supplements. Multiple hydroxylation reactions in several tissues including liver and small intestine produce different forms of vitamin D3. Low serum vitamin D levels is a global problem which may origin from differential absorption following supplementation. The objective of the present study was to estimate the physicochemical properties, metabolism, transport and pharmacokinetic behavior of vitamin D3 derivatives following oral ingestion. GastroPlus software, which is an in silico mechanistically-constructed simulation tool, was used to simulate the physicochemical and pharmacokinetic behavior for twelve vitamin D3 derivatives. The Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) Predictor and PKPlus modules were employed to derive the relevant parameters from the structural features of the compounds. The majority of the vitamin D3 derivatives are lipophilic (log P values > 5) with poor water solubility which are reflected in the poor predicted bioavailability. The fraction absorbed values for the vitamin D3 derivatives were low except for calcitroic acid, 1,23S,25-trihydroxy-24-oxo-vitamin D3, and (23S,25R)-1,25-dihydroxyvitamin D3-26,23-lactone each being greater than 90% fraction absorbed.
    [Show full text]
  • Drug Interactions with Smoke and Smoking Cessation Medications
    Drug Interactions with Smoke and Smoking Cessation Medications Paul Oh MD MSc FRCPC FACP Medical Director, Toronto Rehab Assistant Professor, Division of Clinical Pharmacology, University of Toronto Disclosures • Advisory Boards – Amgen, AstraZeneca, BMS, Janssen, Novartis, Pfizer, Sanofi • Research Funding – Heart & Stroke, CIHR • Professional Affiliations: – CACR, CCN, CDA Objectives • review pharmacokinetic principles – what is the disposition of a medication once ingested? • highlight the role of the drug metabolism cytochrome P450 system as a particular site for many important drug interactions • Case based discussion of common interactions – drug-drug (SCT) and drug-smoke Cased Based Questions 1. What is a “CYP” and what does it do? 2. How can a sinus infection make you pass out? 3. Why is this workout so painful? 4. How do cigarettes and coffee go together? 5. Why is quitting possibly hazardous to your drug health? 6. What makes someone with heart disease and depression slow down? Ingestion First-Pass Metabolism Gut Lumen Gut Wall Liver Fraction Fraction Absorbed Metabolized Portal Circulation Metabolism Metabolism Drug Metabolism in the Liver SYSTEMIC LIVER CIRCULATION Eliminated unchanged by the kidneys To the kidneys for PORTAL VEIN elimination Drug Metabolism in the Liver SYSTEMIC LIVER CIRCULATION Eliminated unchanged by the kidneys P-450 OH Phase I metabolism Phase II metabolism Glucuronide OH Phase II metabolism Sulfate To the kidneys for PORTAL VEIN elimination Hepatocytes Cytochrome P450 Overview of Pharmacology Concepts Cytochrome P450 System • Nomenclature: e.g., CYP3A4 – "CYP" = cytochrome P450 protein abbreviation – family; subfamily; isoform • The most important isoforms are CYP3A4, CYP2D6, CYP1A2 – anticipate drug interactions if prescribing drugs using these enzymes.
    [Show full text]
  • Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations: a Comprehensive Review of the Human Data
    Journal of Personalized Medicine Review Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations: A Comprehensive Review of the Human Data Navid Neyshaburinezhad 1 , Hengameh Ghasim 1, Mohammadreza Rouini 1, Youssef Daali 2,3,4,* and Yalda H. Ardakani 1,* 1 Biopharmaceutics and Pharmacokinetic Division, Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran 14176-14411, Iran; [email protected] (N.N.); [email protected] (H.G.); [email protected] (M.R.) 2 Division of Clinical Pharmacology and Toxicology, Geneva University Hospitals, 1205 Geneva, Switzerland 3 Faculty of Medicine, University of Geneva, 1206 Geneva, Switzerland 4 Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1211 Geneva, Switzerland * Correspondence: [email protected] (Y.D.); [email protected] (Y.H.A.) Abstract: Genetic polymorphisms in cytochrome P450 genes can cause alteration in metabolic activity of clinically important medicines. Thus, single nucleotide variants (SNVs) and copy number variations (CNVs) in CYP genes are leading factors of drug pharmacokinetics and toxicity and form pharmacogenetics biomarkers for drug dosing, efficacy, and safety. The distribution of cytochrome P450 alleles differs significantly between populations with important implications for personalized Citation: Neyshaburinezhad, N.; drug therapy and healthcare programs. To provide a meta-analysis of CYP allele polymorphisms Ghasim, H.; Rouini, M.; Daali, Y.; with clinical importance, we brought together whole-genome and exome sequencing data from Ardakani, Y.H. Frequency of 800 unrelated individuals of Iranian population (100 subjects from 8 major ethnics of Iran) and Important CYP450 Enzyme Gene 63,269 unrelated individuals of five major human populations (EUR, AMR, AFR, EAS and SAS).
    [Show full text]
  • Recent Advances in P450 Research
    The Pharmacogenomics Journal (2001) 1, 178–186 2001 Nature Publishing Group All rights reserved 1470-269X/01 $15.00 www.nature.com/tpj REVIEW Recent advances in P450 research JL Raucy1,2 ABSTRACT SW Allen1,2 P450 enzymes comprise a superfamily of heme-containing proteins that cata- lyze oxidative metabolism of structurally diverse chemicals. Over the past few 1La Jolla Institute for Molecular Medicine, San years, there has been significant progress in P450 research on many fronts Diego, CA 92121, USA; 2Puracyp Inc, San and the information gained is currently being applied to both drug develop- Diego, CA 92121, USA ment and clinical practice. Recently, a major accomplishment occurred when the structure of a mammalian P450 was determined by crystallography. Correspondence: Results from these studies will have a major impact on understanding struc- JL Raucy,La Jolla Institute for Molecular Medicine,4570 Executive Dr,Suite 208, ture-activity relationships of P450 enzymes and promote prediction of drug San Diego,CA 92121,USA interactions. In addition, new technologies have facilitated the identification Tel: +1 858 587 8788 ext 116 of several new P450 alleles. This information will profoundly affect our under- Fax: +1 858 587 6742 E-mail: jraucyȰljimm.org standing of the causes attributed to interindividual variations in drug responses and link these differences to efficacy or toxicity of many thera- peutic agents. Finally, the recent accomplishments towards constructing P450 null animals have afforded determination of the role of these enzymes in toxicity. Moreover, advances have been made towards the construction of humanized transgenic animals and plants. Overall, the outcome of recent developments in the P450 arena will be safer and more efficient drug ther- apies.
    [Show full text]
  • Consequences of Exchanging Carbohydrates for Proteins in the Cholesterol Metabolism of Mice Fed a High-Fat Diet
    Consequences of Exchanging Carbohydrates for Proteins in the Cholesterol Metabolism of Mice Fed a High-fat Diet Fre´de´ ric Raymond1.¤a, Long Wang2., Mireille Moser1, Sylviane Metairon1¤a, Robert Mansourian1, Marie- Camille Zwahlen1, Martin Kussmann3,4,5, Andreas Fuerholz1, Katherine Mace´ 6, Chieh Jason Chou6*¤b 1 Bioanalytical Science Department, Nestle´ Research Center, Lausanne, Switzerland, 2 Department of Nutrition Science and Dietetics, Syracuse University, Syracuse, New York, United States of America, 3 Proteomics and Metabonomics Core, Nestle´ Institute of Health Sciences, Lausanne, Switzerland, 4 Faculty of Science, Aarhus University, Aarhus, Denmark, 5 Faculty of Life Sciences, Federal Institute of Technology, Lausanne, Switzerland, 6 Nutrition and Health Department, Nestle´ Research Center, Lausanne, Switzerland Abstract Consumption of low-carbohydrate, high-protein, high-fat diets lead to rapid weight loss but the cardioprotective effects of these diets have been questioned. We examined the impact of high-protein and high-fat diets on cholesterol metabolism by comparing the plasma cholesterol and the expression of cholesterol biosynthesis genes in the liver of mice fed a high-fat (HF) diet that has a high (H) or a low (L) protein-to-carbohydrate (P/C) ratio. H-P/C-HF feeding, compared with L-P/C-HF feeding, decreased plasma total cholesterol and increased HDL cholesterol concentrations at 4-wk. Interestingly, the expression of genes involved in hepatic steroid biosynthesis responded to an increased dietary P/C ratio by first down- regulation (2-d) followed by later up-regulation at 4-wk, and the temporal gene expression patterns were connected to the putative activity of SREBF1 and 2.
    [Show full text]
  • Glyphosate's Suppression of Cytochrome P450 Enzymes
    Entropy 2013, 15, 1416-1463; doi:10.3390/e15041416 OPEN ACCESS entropy ISSN 1099-4300 www.mdpi.com/journal/entropy Review Glyphosate’s Suppression of Cytochrome P450 Enzymes and Amino Acid Biosynthesis by the Gut Microbiome: Pathways to Modern Diseases Anthony Samsel 1 and Stephanie Seneff 2,* 1 Independent Scientist and Consultant, Deerfield, NH 03037, USA; E-Mail: [email protected] 2 Computer Science and Artificial Intelligence Laboratory, MIT, Cambridge, MA 02139, USA * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-617-253-0451; Fax: +1-617-258-8642. Received: 15 January 2013; in revised form: 10 April 2013 / Accepted: 10 April 2013 / Published: 18 April 2013 Abstract: Glyphosate, the active ingredient in Roundup®, is the most popular herbicide used worldwide. The industry asserts it is minimally toxic to humans, but here we argue otherwise. Residues are found in the main foods of the Western diet, comprised primarily of sugar, corn, soy and wheat. Glyphosate's inhibition of cytochrome P450 (CYP) enzymes is an overlooked component of its toxicity to mammals. CYP enzymes play crucial roles in biology, one of which is to detoxify xenobiotics. Thus, glyphosate enhances the damaging effects of other food borne chemical residues and environmental toxins. Negative impact on the body is insidious and manifests slowly over time as inflammation damages cellular systems throughout the body. Here, we show how interference with CYP enzymes acts synergistically with disruption of the biosynthesis of aromatic amino acids by gut bacteria, as well as impairment in serum sulfate transport. Consequences are most of the diseases and conditions associated with a Western diet, which include gastrointestinal disorders, obesity, diabetes, heart disease, depression, autism, infertility, cancer and Alzheimer’s disease.
    [Show full text]
  • Pharmacogenetics of Cytochrome P450 and Its Application and Value in Drug Therapy – the Past, Present and Future
    Pharmacogenetics of cytochrome P450 and its application and value in drug therapy – the past, present and future Magnus Ingelman-Sundberg Karolinska Institutet, Stockholm, Sweden The human genome x 3,120,000,000 nucleotides x 23,000 genes x >100 000 transcripts (!) x up to 100,000 aa differences between two proteomes x 10,000,000 SNPs in databases today The majority of the human genome is transcribed and has an unknown function RIKEN consortium Science 7 Sep 2005 Interindividual variability in drug action Ingelman-Sundberg, M., J Int Med 250: 186-200, 2001, CYP dependent metabolism of drugs (80 % of all phase I metabolism of drugs) Tolbutamide Beta blokers Warfarin Antidepressants Phenytoin CYP2C9* Diazepam Antipsychotics NSAID Citalopram Dextromethorphan CYP2D6* CYP2C19* Anti ulcer drugs Codeine CYP2E1 Clozapine Debrisoquine CYP1A2 Ropivacaine CYP2B6* Efavirenz Cyclophosphamide CYP3A4/5/7 Cyclosporin Taxol Tamoxifen Tacrolimus 40 % of the phase I Amprenavir Amiodarone metabolism is Cerivastatin carried out by Erythromycin polymorphic P450s Methadone Quinine (enzymes in Italics) Phenotypes and mutations PM, poor metabolizers; IM, intermediate met; EM, efficient met; UM, ultrarapid met Frequency Population Homozygous based dosing for • Stop codons • Heterozygous Two funct deleterious • Deletions alleles SNPs • Deleterious • Gene missense • Unstable duplication SNPs protein • Induction • Splice defects EM PM IM UM Enzyme activity/clearance The Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee http://www.imm.ki.se/CYPalleles/ Webmaster: Sarah C Sim Editors: Magnus Ingelman-Sundberg, Ann K. Daly, Daniel W. Nebert Advisory Board: Jürgen Brockmöller, Michel Eichelbaum, Seymour Garte, Joyce A. Goldstein, Frank J. Gonzalez, Fred F. Kadlubar, Tetsuya Kamataki, Urs A.
    [Show full text]
  • Drug–Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes
    pharmaceutics Review Drug–Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes Florian Klomp 1, Christoph Wenzel 2 , Marek Drozdzik 3 and Stefan Oswald 1,* 1 Institute of Pharmacology and Toxicology, Rostock University Medical Center, 18057 Rostock, Germany; fl[email protected] 2 Department of Pharmacology, Center of Drug Absorption and Transport, University Medicine Greifswald, 17487 Greifswald, Germany; [email protected] 3 Department of Experimental and Clinical Pharmacology, Pomeranian Medical University, 70-111 Szczecin, Poland; [email protected] * Correspondence: [email protected]; Tel.: +49-381-494-5894 Received: 9 November 2020; Accepted: 8 December 2020; Published: 11 December 2020 Abstract: Cytochrome P450 (CYP) 1A enzymes are considerably expressed in the human intestine and liver and involved in the biotransformation of about 10% of marketed drugs. Despite this doubtless clinical relevance, CYP1A1 and CYP1A2 are still somewhat underestimated in terms of unwanted side effects and drug–drug interactions of their respective substrates. In contrast to this, many frequently prescribed drugs that are subjected to extensive CYP1A-mediated metabolism show a narrow therapeutic index and serious adverse drug reactions. Consequently, those drugs are vulnerable to any kind of inhibition or induction in the expression and function of CYP1A. However, available in vitro data are not necessarily predictive for the occurrence of clinically relevant drug–drug interactions. Thus, this review aims to provide an up-to-date summary on the expression, regulation, function, and drug–drug interactions of CYP1A enzymes in humans. Keywords: cytochrome P450; CYP1A1; CYP1A2; drug–drug interaction; expression; metabolism; regulation 1. Introduction The oral bioavailability of many drugs is determined by first-pass metabolism taking place in human gut and liver.
    [Show full text]
  • CYP1A2 164 a C Polymorphism, Cigarette Smoking, Consumption of Well-Done Red Meat and Risk of Developing Colorectal Adenomas and Carcinomas MONA SÆBØ 1* , CAMILLA F
    ANTICANCER RESEARCH 28 : 2289-2296 (2008) ¡ CYP1A2 164 A C Polymorphism, Cigarette Smoking, Consumption of Well-done Red Meat and Risk of Developing Colorectal Adenomas and Carcinomas MONA SÆBØ 1* , CAMILLA F. SKJELBRED 1,2* , KARIN BREKKE LI 1, INGER MARIE BOWITZ LOTHE 3, PER CHR. HAGEN 1, EGIL JOHNSEN 4, KJELL M. TVEIT 5 and ELIN H. KURE 1,3,5 1Telemark University College, Faculty of Arts and Sciences, Bø i Telemark; 2Department of Laboratory Medicine, Section of Medical Genetics, Telemark Hospital, Skien; Departments of 3Pathology, 4Surgery and 5Oncology, Ulleval University Hospital, Oslo, Norway Abstract. Background: Genetic polymorphisms in sporadic colorectal adenomas and carcinomas has been metabolizing enzymes may modify the association of associated with several lifestyle factors, including cigarette environmental exposure on colorectal cancer (CRC) and smoking (4, 5) and dietary items such as red meat (6-8). adenoma risk. Material s and Methods: One hundred and Cigarette smoke is a major source of a wide variety of ninety-eight CRC cases, 422 adenomas (206 low-risk and carcinogens, including nitrosamines, polycyclic hydrocarbons 216 high-risk adenomas) and 222 controls were genotyped (PAHs), aromatic amines (AAs) and heterocyclic aromatic ¡ for the CYP1A2 164 A C polymorphism and questionnaires amines (HCAs) (9, 10). Carcinogens in cigarettes may reach were used to assess environmental exposure. Results: The the colorectal mucosa through the circulatory system (11, smoking parameter “current smoking” was significantly 12). Long-term, heavy cigarette smokers have a 2- to 3-fold associated with CRC risk, and all the smoking parameters elevated risk of colorectal adenoma and the vast majority of related to current smoking, having ever smoked or high studies in the past several years show an association between numbers of cigarette years were significantly associated with cigarette use and CRC (4, 13).
    [Show full text]
  • Making Sense of CYP2D6 and CYP1A2 Genotype Vs Phenotype
    Savvy Psychopharmacology Making sense of CYP2D6 and CYP1A2 genotype vs phenotype O. Greg Deardorff, PharmD, BCPP, Victoria Jenne, PharmD, MPH, BCPS, and Lauren Leonard, PharmD he clinical response to the same dose Phenoconversion occurs when these factors of a drug may vary among individu- result in a phenotype that is different from T als. Cytochrome P450 (CYP) 2D6 and that predicted by genotype. Because of the 1A2 are enzymes that metabolize many possibility of phenoconversion, knowing a psychotropic medications. Genetic varia- patient’s genotype may be of limited value tions in these enzymes may cause changes in making clinical decisions. This article in their activity and result in differences in provides guidance on interpreting both the Vicki L. Ellingrod, effectiveness and adverse effects. Although genotype and phenotype of CYP2D6 and PharmD, FCCP pharmacogenetic testing is available for CYP1A2. For 2 case reports that illustrate the Department Editor CYP2D6 and CYP1A2, interpretation and concepts discussed, see the online version of clinical application of the results may not be this article at MDedge.com/psychiatry. straightforward. Genetic variations in CYP450 enzymes CYP2D6 determine enzymatic activity, which can The enzyme activity of CYP2D6 varies have a large effect on drug levels, efficacy, among individuals and may include no and toxicity. However, there are many other activity, decreased activity, normal activ- important factors that clinicians should con- ity, or increased activity. After obtaining the sider when trying to predict the effects of genotype, the activity level of the CYP2D6 medications. While clinicians often focus alleles may be determined. The frequency on a patient’s genotype, this only provides with which certain alleles occur varies with information on a chromosomal level, and ancestry.
    [Show full text]